Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Current Deferred Revenue: 2009-2024

Historic Current Deferred Revenue for Lifecore Biomedical (LFCR) over the last 16 years, with May 2024 value amounting to $10.6 million.

  • Lifecore Biomedical's Current Deferred Revenue rose 4.73% to $9.0 million in Q4 2024 from the same period last year, while for Nov 2024 it was $9.0 million, marking a year-over-year increase of 4.73%. This contributed to the annual value of $10.6 million for FY2024, which is 51.17% up from last year.
  • Per Lifecore Biomedical's latest filing, its Current Deferred Revenue stood at $10.6 million for FY2024, which was up 51.17% from $7.0 million recorded in FY2023.
  • Over the past 5 years, Lifecore Biomedical's Current Deferred Revenue peaked at $10.6 million during FY2024, and registered a low of $287,000 during FY2021.
  • In the last 3 years, Lifecore Biomedical's Current Deferred Revenue had a median value of $7.0 million in 2023 and averaged $6.2 million.
  • In the last 5 years, Lifecore Biomedical's Current Deferred Revenue dropped by 29.46% in 2020 and then skyrocketed by 661.70% in 2023.
  • Yearly analysis of 5 years shows Lifecore Biomedical's Current Deferred Revenue stood at $352,000 in 2020, then declined by 18.47% to $287,000 in 2021, then soared by 220.21% to $919,000 in 2022, then surged by 661.70% to $7.0 million in 2023, then surged by 51.17% to $10.6 million in 2024.